Ivacaftor in cystic fibrosis adults: Czech experience with six years of follow-up
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F16%3A10324861" target="_blank" >RIV/00064203:_____/16:10324861 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11130/16:10324861
Result on the web
<a href="http://dx.doi.org/10.5507/bp.2016.029" target="_blank" >http://dx.doi.org/10.5507/bp.2016.029</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.5507/bp.2016.029" target="_blank" >10.5507/bp.2016.029</a>
Alternative languages
Result language
angličtina
Original language name
Ivacaftor in cystic fibrosis adults: Czech experience with six years of follow-up
Original language description
Aims. Ivacaftor is a revolutionary treatment option for cystic fibrosis (CF) patients with G551D and other gating mutations. The aim of this study was to evaluate the clinical status of patients on ivacaftor who were followed for up to 6 years together with an evaluation of ivacaftor therapy in one patient with an initial FEV1 less than 40% of predicted value. Methods. Data on development of clinical status and sinopulmonary-related therapies were obtained from patient health records during ivacaftor treatment lasting for up to six years and were compared with an equivalent period before ivacaftor administration. Results. Five CF adults with a median age 28.6 years (range 21.4-35.6 years) with median FEV1 45% pred. (range 16-85% pred.) were included in the study. Four subjects were also participants in the STRIVE and PERSIST studies. Altogether, twenty-four patient-years of ivacaftor treatment were analyzed. The median FEV1 decline per year decreased from -4.5 to -0.9% pred. (P = 0.043). Reduction in number of days on antibiotic treatment and hospital stays was 21% (P < 0.001) and 75% (P = 0.003), respectively. Improvement and stabilization of lung function was observed for up to six years of treatment. In a patient with severe airway obstruction, an increase in the FEV1 value (30.4% from baseline) was documented during the first twelve months of treatment. Conclusion. Ivacaftor therapy resulted in improved and stabilized lung function in up to six years of treatment with a reduction in number of days on antibiotic treatment and hospital stays. Its efficiency was also displayed in a patient with severe airway obstruction.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FC - Pneumology
OECD FORD branch
—
Result continuities
Project
<a href="/en/project/LD14073" target="_blank" >LD14073: Implementation of next generation sequencing in CZ: ethical and clinical genetic indication issues</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Biomedical Papers
ISSN
1213-8118
e-ISSN
—
Volume of the periodical
160
Issue of the periodical within the volume
2
Country of publishing house
CZ - CZECH REPUBLIC
Number of pages
4
Pages from-to
276-279
UT code for WoS article
000379360500015
EID of the result in the Scopus database
2-s2.0-84976344716